NEW YORK CITY — A single dose of an LSD-containing investigational drug rapidly alleviated symptoms of moderate-to-severe generalized anxiety disorder (GAD), a phase IIb randomized trial showed.
Tested at four doses — 25, 50, 100, and 200 μg — the 100-μg dose of MM120 yielded the highest level of clinical activity, significantly reducing Hamilton Anxiety Rating Scale (HAM-A) total score by 7.7 points compared with placebo by week 12 (-21.9 vs -14.2, P<0.003), reported Daniel Karlin, MD, chief medical officer of drugmaker MindMed, at the American Psychiatric Associationopens in a new tab or window annual meeting.
Furthermore, 65% of the patients on the 100-μg dose had a clinical response rate (a ≥50% improvement in HAM-A) and 48% were in clinical remission (HAM-A score of 7 or less).
“The idea that a single dose of drug could produce almost 50% remission rate for people suffering from moderate-to-severe anxiety 12 weeks after treatment — pretty remarkable,” Karlin told MedPage Today.
So many people have bad anxiety as part of long covid. This could be a lifesaver for many.
